ESEmily Le Souder

Emily Le Souder

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Emily Le Souder has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The effect of a simultaneous versus a staged resection of metastatic colorectal cancer on time to adjuvant chemotherapy

    by Emily Le Souder, Arash Azin, Trevor Wood, Dhruvin Hirpara, Ahmad Elnahas, Sean Cleary, Alice Wei, Richard Walker, Armen Parsyan, Sami Chadi, et al.

    Background and Objectives: Patients with colorectal cancer with synchronous liver metastases may undergo a staged or a simultaneous resection. This study aimed to determine whether the time to adjuvant chemotherapy was delayed in patients undergoing a simultaneous resection.Methods: A retrospective cohort study was conducted between 2005 and 2016. The primary outcome was time to adjuvant chemotherapy. A multivariate linear regression was conducted to ascertain the adjusted effect of a simultaneous versus a staged approach on time to adjuvant chemotherapy.Results: A total of 155 patients were included. A total of 127 patients underwent a staged resection, whereas 28 patients underwent a simultaneous resection. Age, sex, and American Society of Anesthesiologists class as well tumor, node, metastasis stage, tumor location, and number and size of metastases were not significantly different between the groups. The median time to adjuvant chemotherapy was 70 and 63 days for the staged and simultaneous groups, respectively (P = .27). Multivariate analysis did not demonstrate an increased propensity for prolonged time to chemotherapy after simultaneous resection (rate ratio: 0.97, 95% CI: 0.71‐1.32, P = .84). There were no significant differences in the length of stay, complications, overall survival, and disease‐free survival between the groups (P > .05).Conclusions: This study demonstrated that simultaneous resection does not result in significant delay of adjuvant chemotherapy compared with a staged approach.


  • Considering the cost of a simultaneous versus staged approach to resection of colorectal cancer with synchronous liver metastases in a publicly funded healthcare model

    by Emily B. Le Souder, Arash Azin, Dhruvin H. Hirpara, Richard Walker, Sean Cleary, Fayez Quereshy

    Background: Simultaneous resection for colorectal cancer with synchronous liver metastases is an established alternative to a staged approach. This study aimed to compare these approaches with regards to economic parameters and short‐term outcomes.Methods: A retrospective cohort analysis was conducted between 2005 and 2016. The primary outcome was cost per episode of care. Secondary measures included 30‐day clinical outcomes. A multivariate analysis was performed to determine the adjusted effect of a simultaneous surgical approach on total cost of care.Results: Fifty‐three cases were identified; 27 in the staged approach, and 26 in the simultaneous group. Age (P = 0.49), sex (P = 0.20), BMI (P = 0.74), and ASA class (P = 0.44) were comparable between groups. Total cost ($20297 vs $27522), OR ($6830 vs $10376), PACU ($675 vs $1182), ward ($7586 vs $11603) and pharmacy costs ($728 vs $1075) were significantly less for the simultaneous group (P < 0.05). The adjusted rate ratio for total cost of care in the staged group compared to simultaneous group was 1.51 (95%CI: 1.16‐1.97, P < 0.05). The groups had comparable Clavien‐Dindo scores (P = 0.89), 30‐day readmissions (P = 0.44), morbidity (P = 0.50) and mortality (P = 1.00).Conclusions: Our study demonstrates that a simultaneous approach is associated with a significantly lower total cost while maintaining comparable short‐term outcomes.


  • Comparison of two novel staging systems with the TNM system in predicting stage III colon cancer survival

    by Richard Walker, Trevor Wood, Emily LeSouder, Michelle Cleghorn, Manjula Maganti, Andrea MacNeill, Fayez A. Quereshy

    Background and Objectives: Adaptations of the TNM staging system that incorporate the Lymph Node Ratio (LNR) have been proposed for stage III colon cancer. This study compared the concordance of two novel staging systems and the TNM system with observed survival outcomes in stage III patients.Methods: A review of patients who underwent surgery for stage III colon cancer between January 2002 and April 2015 at a tertiary care centre was performed. The Kaplan‐Meier method was used to estimate the 5‐year overall (OS) and disease free survival (DFS) rates, and the concordance probability was calculated to evaluate the discriminatory power of the staging systems.Results: Two hundred and sixty‐one patients were identified. For TNM stages IIIA, IIIB, and IIIC, 5‐year OS was 83.4%, 67.6%, and 38.3%, respectively (P < 0.001). All three staging systems were independently predictive of OS and DFS (P < 0.001). However, the novel staging system by Sugimoto et al18 was the most favourable prognostic tool, with a concordance of 0.646 for DFS and 0.659 for OS.Conclusions: The novel staging system by Sugimoto et al18 was superior to the TNM system. Incorporating LNR into staging models for node positive colon cancers may improve survival information available to patients and potentially aid treatment decisions.


  • Long-Term Outcomes of Resection for Locoregionally Recurrent Colon Cancer: A Multi-Centered Retrospective Descriptive Cohort Study

    by Tyler R. Chesney, Jeffrey J. Metz, Ashlie Nadler, Fayez A. Quereshy, Shady Ashamalla, Sergio A. Acuna, Carol J. Swallow